Given the relative scarcity of HER2 mutations, the observational genomic-screening protocol HER-Seq (NCT03786107) was designed to identify patients potentially eligible to enroll into neratinib treatment protocols such as SUMMIT, by performing HER2-targeted next-generation sequencing on plasma collected from patients with metastatic breast or cervical cancer. Here, ERBB2 is linked to cervical cancer.